CCND1 overexpression
|
Mantle Cell Lymphoma
|
CCND1 overexpression
|
Mantle Cell Lymphoma
|
INCB50465 Sensitive: C2 – Inclusion Criteria
|
INCB50465 Sensitive: C2 – Inclusion Criteria
|
CCND1 overexpression
|
Breast Cancer
|
CCND1 overexpression
|
Breast Cancer
|
AMG 386 Resistant: C3 – Early Trials
|
AMG 386 Resistant: C3 – Early Trials
|
CCND1 overexpression
|
Breast Cancer
|
CCND1 overexpression
|
Breast Cancer
|
ABT-888 Resistant: C3 – Early Trials
|
ABT-888 Resistant: C3 – Early Trials
|
CCND1 overexpression
|
Multiple Myeloma
|
CCND1 overexpression
|
Multiple Myeloma
|
bortezomib Sensitive: C3 – Early Trials
|
bortezomib Sensitive: C3 – Early Trials
|
CCND1 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
CCND1 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Resistant: C3 – Early Trials
|
tamoxifen Resistant: C3 – Early Trials
|
CCND1 overexpression
|
Squamous Cell Skin Cancer
|
CCND1 overexpression
|
Squamous Cell Skin Cancer
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
CCND1 overexpression
|
Ependymoma
|
CCND1 overexpression
|
Ependymoma
|
abemaciclib Sensitive: D – Preclinical
|
abemaciclib Sensitive: D – Preclinical
|